Felix Gonzalez Lopez De Turiso

This inventor holds 26 USPTO granted patents and 24 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Cancer Therapeutics. Top assignees: Amgen Inc., Biogen Ma Inc., Cytokinetics, Inc.. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Felix Gonzalez Lopez De Turiso. Retrieved from https://idiyas.com/inventor/felix-gonzalez-lopez-de-turiso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 24)

% Patents Active = 84.6

CIPO Patents = 6 (Patent Applications = 7)

EPO Patents = 13 (Patent Applications = 31)

Average Co-Inventor Count = 6.6

ph-index = 6

Forward Citations = 79(Granted Patents)

Location History:

San Mateo, CA (US) (2012 - 2018)
Cambridge, MA (US) (2017 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

ASK1 Inhibitors

MDM2 Inhibitors

Bisamide Compounds

Heterocyclic Compounds

Pyridine Macrocycle

Tricyclic Inhibitors

Sarcomere Activating

Piperidinone Derivatives

Quinoline Derivatives

Cancer Treatment

Protein Inhibition

Compounds Development

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404263 - ASK1 inhibiting agents (2025-09-02),

2. 11999715 - ASK1 inhibiting agents (2024-06-04),

3. 11897898 - Pyridine macrocycle compounds as ASK1 inhibiting agents (2024-02-13),

4. 11814362 - ASK1 inhibiting agents (2023-11-14),

5. 11780826 - Bisamide sarcomere activating compounds and uses thereof (2023-10-10),

6. 11407721 - CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer (2022-08-09),

7. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),

8. 11299479 - Bisamide sarcomere activating compounds and uses thereof (2022-04-12),

9. 11168095 - ASK1 inhibiting agents (2021-11-09),

10. 10899746 - Bisamide sarcomere activating compounds and uses thereof (2021-01-26),

11. 10723720 - Bisamide sarcomere activating compounds and uses therof (2020-07-28),

12. 9873704 - Heterocyclic compounds and their uses (2018-01-23),

13. 9873701 - Heterocyclic compounds and their uses (2018-01-23),

14. 9593129 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2017-03-14),

15. 9376425 - Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer (2016-06-28),

Title: Innovator Spotlight: Felix Gonzalez Lopez De Turiso

Introduction:

Felix Gonzalez Lopez De Turiso is a prolific inventor based in San Mateo, CA (US) with an impressive track record in the field of pharmaceuticals. With 21 patents to his name, his contributions to the world of medicine and cancer treatment are truly remarkable.

Latest Patents:

Two of his latest patents showcase his innovative approach to developing life-saving compounds. The first patent focuses on Bisamide sarcomere activating compounds and their therapeutic uses, while the second patent delves into the use of CIS-morpholinone and other compounds as MDM2 inhibitors for cancer treatment.

Career Highlights:

Felix Gonzalez Lopez De Turiso has made significant contributions to the pharmaceutical industry through his work with renowned companies such as Amgen Inc. and Cytokinetics, Inc. His expertise and dedication have been instrumental in advancing the field of cancer research and drug development.

Collaborations:

Throughout his career, Felix Gonzalez Lopez De Turiso has collaborated with esteemed professionals in the industry, including his coworkers Michael G Johnson and Timothy David Cushing. These collaborations have led to groundbreaking discoveries and the development of novel treatments for various medical conditions.

Conclusion:

In conclusion, Felix Gonzalez Lopez De Turiso is a visionary inventor whose innovative research and patents have had a profound impact on the field of pharmaceuticals. His commitment to advancing medical science and improving patient outcomes continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.